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Adoptive immunotherapy for the treatment of melanoma has attracted growing interest in 
recent years. The trend reflects, at least in part, the disappointing results of conventional 
chemotherapy to induce lasting remission in advanced stages of the disease with multiple 
metastases and to cure patients even after initially complete response. The isolation of tumor 
infiltrating T cells from melanoma lesions, the identification of melanomaassociated 
antigens and the significant progress in our understanding in redirecting an immune 
response favored the development of novel strategies in adoptive immunotherapy of 
melanoma. Most recent advances in selectively eliminating melanoma cell subsets from 
tumor tissues together with the identification of socalled melanoma stem cells, however, 
imply to redefine the therapeutic target in melanoma. The review discusses current 












Despite of major improvements in the therapy of melanoma, the frequency of partial or 
complete responses after chemo and radiotherapy has not significantly risen since years 
(Garbe et al. 2010). Disseminated melanoma is still an incurable disease and overall survival 
correlates with the stage of the disease at time of diagnosis. A 10yearsurvival rate of 75
85% can be reached when the primary tumor was diagnosed in stage I or II, melanoma in 
stage III or IV, however, is commonly associated with poor survival (Garbe et al. 2010). The 
situation is mainly caused by two major drawbacks due to the particular biology of 
melanoma cells. Firstly, melanoma early disseminates into distant organs including the 
brain by forming micrometastases which are small in cancer cell numbers and beyond the 
detection limit of current tomographic procedures (Denninghoff et al. 2004; Bedikian et al. 
2010). Micrometastases can persist for long time without any change in size in a “dormant” 
stage (Leiter et al. 2010). Secondly, many melanoma cells are notoriously resistant against 
chemo and radiation therapy (Bradbury & Middleton 2004; Pak et al. 2001; Pak et al. 2004). 
Both drawbacks result in the unsatisfactory situation that surgical removing of tumor 
lesions in early stages is the only curative option to fight melanoma. In more progressed 
stages of the disease recruitment of the cellular immune defense is thought to be an option. 









although are not curative (Kirkwood et al. 2000; Kirkwood et al. 1996) and still a matter of 
debate. These efforts, however, indicate that activation of the patient’s immune response can 
be effective in fighting melanoma; a more tumorspecific way of immune cell activation 
needs to be explored. We here summarize evidence for the potency of adoptive immune cell 









Based on early evidences that the concerted action of the immune system is capable to fight 
cancer efforts were focused to redirect cytolytic effector cells towards autologous cancer 
cells. First experiments following the strategy were performed by the Rosenberg group in 
1984 by treating transplanted tumors in mice by adoptive transfer of syngeneic lymphocytes 
in combination with IL2 (Rosenberg 1984; Grimm et al. 1982). In addition to promote 
activation and proliferation of both cytolytic and helper T cells, IL2 also activates natural 
killer (NK) cells as well as macrophages (Waldmann & Tagaya 1999) which provided the 
rationale to administer IL2 as immune adjuvant in cancer patients. Between 1985 and 1993 
overall 270 melanoma patients were treated with IL2 in the context of eight clinical trials 
with an objective response rate of 16%, comprising 6% complete and 10% partial responses 
(Atkins et al. 1999). While IL2 doubtless induced an immune cell antitumor response, the 
immune cell activation was not specifically redirected towards melanoma. 
The elucidation of socalled “tumor antigens” preferentially expressed on melanoma cells 
led to the concept to immunize patients with defined T cell antigens in order to activate by 
natural selection melanoma specific T cells in a more specific fashion. Two antigens were 
primarily considered as promising candidates, namely MelanA/MART 1 and gp100 
(Rivoltini et al. 1996; Rivoltini et al. 1995). By using different strategies of vaccination 
including injection of antigen or application of antigenpulsed dendritic cells melanoma 
reactive T cells could be amplified in the cancer patient (Kawakami & Rosenberg 1997). 
Until today a variety of clinical studies using dendritic cells loaded with T cell recognition 
peptides were performed with various therapeutic effects. A metaanalysis in 2008 
comprising 38 trials with overall 626 patients revealed that 3% of the patients responded to 
treatment with complete and 6% with partial remission, 21% achieved stable disease 
(EngellNoerregaard et al. 2009). These results were irrespective of both the antigen used for 
loading and the type of DCs. The route of injection and the administration of adjuvant had 
no impact on clinical outcome. In conclusion no therapeutic advantage could be 
documented for patients treated with vaccines compared to treatment with immune 
stimulatory cytokines. 
As a consequence further developments in the immunotherapy of melanoma were thereon 
focused on the adoptive transfer of immune effector cells itself. The development was 
further strengthened by the success in isolating tumor infiltrating lymphocytes (TILs) which 
are found in substantial numbers in a variety of melanoma lesions. First described in 1969 
(Clark et al. 1969) TILs particularly from melanoma gained interest in during the last years 
since these cells are believed to recognize melanomaassociated antigens and thereby 
specifically accumulate in melanoma lesions. Freshly isolated from melanoma lesions TILs 
are mainly of T cell origin consisting of both effector and helper T cell subsets. While the 
prevalence of TILs in primary melanoma lesions and metastases is not a prognostic factor 
itself, high numbers of infiltrating lymphocytes, however, correlate with better clinical 







these lymphocytes as effector cells in the treatment of melanoma. Protocols according to 
GMP standards were developed to isolate TILs and to amplify them ex vivo to numbers 
suitable for reinfusion (Figure 1). To expand preferentially highly melanoma reactive T cells 
first lymphocyte expansion protocols were based on cultures in presence of IL2 on feeder 
layer cells expressing melanoma antigens (Vignard et al. 2005). While the concept perfectly 
worked in mouse models, the application in patients turned out to need further 
improvements. Upon adoptive TIL infusions regression of metastases could be observed in 
the majority of patients, only few, however, remained in complete remission (Besser et al. 
2010). In most cases a partial shrinkage of the tumor mass followed by stable disease was 
observed. The disappointing results despite the high numbers of infused TILs is thought to 
be due to the fact that the cells were extensively amplified over weeks ex vivo and have 
entered anergy unable to be properly rescued for an antimelanoma attack after infusion 
(Chhabra 2010). More recent expansion protocols therefore aim to select socalled “young 
TILs” which underwent minimal culture times and which were not selected for melanoma 
reactivity prior reinfusion. A first phase I trial showed improved response with increased 
frequencies in partial and complete remission (Besser et al. 2009). All trials were performed 
under myeloablative conditions and IL2 administration based on the rationale to provide 
space and stimuli for homeostatic expansion of adoptively transferred T cells. Other 
cytokines like IL7 and/or IL15 are worth to be explored since they do not activate 
regulatory T cells. 
 
 
Fig. 1. Strategies in the adoptive immunotherapy of melanoma. 
Tumor infiltrating lymphocytes (TIL) are isolated from a melanoma lesion, amplified ex 
vivo and readministered without further modification. Alternatively, T cells from the 
peripheral blood of the melanoma patient are engineered ex vivo to express either a 
chimeric antigen receptor (CAR), which forms a homodimer, or a recombinant T cell 
receptor (TCR), which is composed of the α and β chain, with specificity for a melanoma 










While adoptive transfer of TILs is showing promising efficacy in first trials, attempts are 









for using effector T cells from the peripheral blood is provided by the frequent inability to 
isolate TILs in sufficient amounts from a given melanoma lesion and the more progressed 
proliferative stage of TILs compared to blood T cells. 
To redirect peripheral blood T cells specifically towards melanoma antibodies were 
combined in a bispecific antibody format which targets T cells with by an antiCD3 
antibody as one arm and the melanoma cell with the other arm. Upon application it is 
assumed that bispecific antibodies build a bridge between T cells and melanoma cells 
thereby forcing peripheral blood cytolytic effectors towards their target. Bispecific 
antibodies were directed against melanoma p97, gp100 (Cochlovius et al. 1999), and 
melanoma chondroitin sulfate proteoglycan (MCSP, also called high molecular weight
melanoma associated antigen HMWMAA) (GrosseHovest et al. 1999). Therapeutic potency 
was demonstrated by longterm survival in preclinical models resulting, the efficacy, 
however, critically depends on the number of recruitable effector cells at the tumor site. Bi
specific constructs triggering CD28 costimulation of T cells furthermore increased tumorcell 
killing predominantly by recruiting cytolytic cells without targeted specificity (Grosse
Hovest et al. 1999; GrosseHovest et al. 2003).  
While first generation bispecific reagents were conventional heterodimeric antibodies, 
second generation antibodies are constituted of two single polypeptide chain antibodies 
covalently joined by a linker domain (GrosseHovest et al. 1999; Bluemel et al. 2010a). Those 
socalled bispecific T cell engager (BiTE) antibodies targeting CD3 on T cells and a tumor
associated antigen on malignant cells of solid tumors showed efficacy even in nanomolar 
concentrations in a clinical trial (Bargou et al. 2008). The size of antigen as well as the 
targeted epitope impacts the efficacy in T cell activation since a BiTE antibody targeting the 
membrane proximal domain of HMWMAA on melanoma cells showed more potent than 
those binding to more distal domains (Bluemel et al. 2010b). The same observations were 
made when targeting EpCAM indicating that there is obviously a correlation between 
epitope positioning relative to the cell membrane and the potency in T cell activation.  
Technical advances in genetically engineering blood T cells ex vivo fueled efforts to design T 
cells with predefined specificity for redirected targeting melanoma cells. Recombinant 
DNA technology and the structural elucidation of the T cell receptor (TCR) complex 
together with recent developments in vector design made the genetic T cell modification 
with a recombinant TCR feasible. The melanoma gp100 specific TCR was one of the first be 
cloned from T cells accumulating at the tumor site. TCR α and β chains were introduced ex 
vivo by retroviral gene transfer into naïve, fresh T cells which gained specificity as indicated 
by redirected cytotoxicity towards primary melanoma and established melanoma cell lines 
and by increased secretion of proinflammatory cytokines including IFNγ (Schaft et al. 
2003; Morgan et al. 2003). TCR modified T cells were amplified ex vivo and reinfused in 
therapeutic doses to the patient (Figure 1). Similarly, recombinant TCRs with specificity for 
MART1/MelanA or MAGEA1 could be transferred into naïve T cells (Hughes et al. 2005; 
Willemsen et al. 2005).  
In 2006 the Rosenberg group published the first clinical trial using T cells with engineered 
specificity for melanoma. Adoptive transfer of those T cells caused a strong response against 
metastases in distant organs. Engineered T cells persisted in circulation of most patients for 
nearly 2 months. The therapeutic efficacy, however, was disappointingly low with 2 out of 
17 patients showing objective regression of metastases resulting in complete response. In 
those patients, interestingly, engineered T cells were detected in the blood for a year after 







immunity (Morgan et al. 2006; Coccoris et al. 2008). In a very recent trial, similarly TCR 
engineered T cells showed efficacy towards brain metastases of melanoma indicating that 
this procedure may be useful to treat otherwise incurable metastatic sites (Hong et al. 2010). 
Although these and other trials showed technical feasibility in engineering TCR modified T 
cells and clinical practicability in the adoptive transfer of those cells, the unexpected low 
clinical response raised concerns with respect to clonal variability of the targeted melanoma 
lesion. 
Melanoma like other malignant diseases displays clonal evolution during tumor progression 
which enables the tumor to evade T cell recognition. Common mechanisms are the down
regulation of MHC complex expression (Seliger 2008), point mutations in the β2 
microglobulin chain (Sigalotti et al. 2004), and deregulation of various components of the 
antigen processing machinery (Seliger 2008; Vitale et al. 2005). As a consequence TCR 
engineered T cells are no longer able to recognize and destroy those melanoma cells with 
mutant or lack of MHCpeptide complexes.  
Limitations in the expression of a recombinant TCR in T cells additionally dampened 
enthusiasm in the strategy. Coexpression of a recombinant TCR together with the 
physiological TCR in T cells turned out to create new but unpredictable specificities which 
may result in severe autoreactivity. The molecular basis is the similarity of the recombinant 
α and β TCR chains to the respective chains of the physiological TCR which leads to the 
formation of heterodimers loosing the specificity of the recombinant TCR (Coccoris et al. 
2010). In mouse models heterodimer formation resulted in severe autoimmunity (Bendle et 
al. 2010). Tremendous efforts were undertaken to solve the problem including replacement 
of TCR constant domains by homologous murine domains (Cohen et al. 2006) and 
introducing cysteine bridges (Kuball et al. 2007) to enforce αβpairing of the recombinant 
TCR chains.  
Advances in the engineering of recombinant signaling molecules facilitated the 
development of a “onechainreceptor” molecule for redirected T cell activation. Zelig 
Eshhar pioneered the strategy in generating a chimeric antigen receptor (CAR) molecule 
composed of an extracellular single chain antibody for binding and an intracellular TCR 
signaling domain (Eshhar et al. 1993). The CAR, also named immunoreceptor or nicknamed 
“Tbody”, thereby combines the MHCindependent recognition of antigen by an antibody 
with the T cell activating machinery of the TCR. Naïve T cells from the peripheral blood of 
melanoma patients are engineered ex vivo to express the CAR, amplified and administered 
to the patient (Figure 1). Due to the modular design a nearly unlimited variety of antigens 
can be targeted as long as an antibody is available, including nonclassical T cell antigens 
like carbohydrates as HMWMAA, also called MCSP (Reinhold et al. 1999). Different CARs 
were reported to target melanoma antigens, including HMWMAA (Reinhold et al. 1999), 
melanotransferrin (Schmidt et al. 2011), GD2 (Yvon et al. 2009) and GD3 (Lo et al. 2010). The 
modular composition of CARs moreover allowed combining primary signaling moieties 
with costimulatory signals in order to modulate the T cell response in a predicted fashion 
(Hombach & Abken 2007). Along with multiple other modifications the stability of 
expression and antigen binding has been substantially improved during the last years 
(Bridgeman et al. 2010). Although CARs use the TCR signaling machinery, the strategy is 
obviously not restricted to redirect T cells; monocytes, macrophages as well as NK cells can 
be specifically redirected by CARs as well (Pegram et al. 2008; Kruschinski et al. 2008). 
Appropriate models and, finally, trials need to address whether redirected nonT cells have 









Some TCRs and CARs specific to melanoma associated antigens are already applied in 
phase I clinical trials, and several others are in an advanced phase of preparation (Table 1). 
Only a few of these studies have been published; other information is derived from 
registries and from personal communications. 
A clinical trial by the Brenner group, Baylor College of Medicine, (Pule et al. 2008) has 
shown a correlation between the persistence of adoptively transferred, modified T cells and 
the clinical outcome. EpsteinBarr virus specific cytotoxic T cells were engineered to express 
a CAR directed to the diasialoganglioside GD2, an antigen expressed by human 
neuroblastoma cells, aiming that redirected T cells would receive optimal costimulation 
after engagement of their EBVspecific TCR, enhancing survival and antitumor activity 
mediated through their CAR (Savoldo et al. 2007). When administered to tumor patients the 
EBVspecific T cells engineered with a GD2specific CAR indeed survived longer than T 
cells with the same CAR but lacking virus specificity. Infusion of these genetically modified 
T cells was associated with tumor regression or necrosis in half of the patients. Results show 
the safety, feasibility, and potential antitumor activity of adoptive therapy with CAR 
modified T cells; clinical application, however, has to take into account some particular 















There are potential balances to advantages of the CAR or the TCR strategy in the adoptive T 
cell therapy of melanoma which need careful consideration. Melanoma cells frequently 
downregulate proteins associated with antigen processing and presentation (Seliger et al. 
1997) which effectively renders the tumor cell invisible to a physiological T cell attack. 
Consequently, the MHCindependent targeting of cell surface molecules through a CAR 
makes those melanoma cells vulnerable to T cell attack while remaining invisible for TCR 
engineered T cells. The CAR strategy moreover has the advantage that immune cells with 
defined specificity for a variety of cell surface molecules can be produced. Powerful 
selection systems, such as phage display provide a plethora of binding domains to target 
virtually any cell surface molecule. Melanoma cells which do not express the targeted 
antigen, however, are not attacked by CAR redirected T cells making antigenloss cell 
variants a source of potential tumour relapse after initially successful treatment. TCR 
redirected T cells, on the other hand, may recognize even those melanoma cells when they 
crosspresent the targeted antigen. Most recently, TCRlike single chain antibodies were 
generated and used as targeting domain in a CAR, thereby combining the MHCrestricted 
recognition of antigen with the CAR strategy. T cells with TCRlike CAR were redirected 
towards NYESO1 and MAGEA1, respectively (StewartJones et al. 2009; Willemsen et al. 
2001). The advantage of these MHC restricted CARs over the use of recombinant TCRs 
remains unclear aside from the fact that the CAR consists of a single expressed protein while 
the TCR approach requires coexpression of both α and β TCR chains.  
The high complexity of the recognition and signaling process in the T cell and the variety of 
antigen structures on the melanoma cell imply that the optimized configuration of a CAR 
universal for each antigen may not exist. In contrast the TCR recognition and activation 
process through MHC presented antigen is much more standardized. The antibodyderived 
binding domain of a CAR moreover displays extraordinary high affinity compared to a 







reduced (StewartJones et al. 2009; Chmielewski et al. 2004). Increase in affinity, however, 
does not necessarily improve CAR redirected T cell activation which is assumed for TCR 
mediated T cell activation as well. CD28 costimulation, moreover, does not impact the 
activation threshold of CAR redirected T cells (Chmielewski et al. 2011). 
Critical to the success of therapy will moreover be the choice of targeted antigen and the 
membrane topography of the targeted epitope. In vitro data suggest that an optimal T cell
totarget cell spacing distance is required for T cell activation. For instance, binding the more 
membrane distal epitope of the targeted antigen showed less T cell activation than binding 
of the membrane proximal epitope (Hombach et al. 2007). The rigidity of the antigen itself as 
well as the antigen mobility in the cell membrane will moreover impact redirected T cell 
activation. Carbohydrate antigens like HMWMAA are thought to act differently than 
polypeptide antigens like melanotransferin, both expressed on the same melanoma cell. As 
such, empirical testing may be required to identify the best targeted epitope for the 
particular antigen for redirected T cell activation. 
The TCR or CAR binding avidity impacts recruitment of engineered T cells to tumor sites. 
Strong binding to target antigen may cause the T cells to be locally trapped while low 
avidity interactions may not provide sufficiently long T cell – melanoma cell contact to 
execute the cytolytic attack. On the other hand, the amount of antigen on the melanoma cell 
surface is also important. In essence, low affinity binding directs the activity of engineered T 
cells preferentially against targets with abundant antigen levels; high affinity binding is 
thought to be also effective against low antigen levels on target cells. The optimized affinity 
which sustains selective T cell trafficking to the tumor, however, is still unclear. Homing 
and migration of engineered T cells may also be manipulated through coexpression of 
chemokine receptors alongside with CARs (Cheadle et al. 2007). Alternatively, isolated T cell 
subpopulations which express or lack certain chemokine receptors may be used, in 
particular when targeting melanoma lesions in the periphery. Studies investigating these 
issues in animal models are now gaining momentum and are likely to improve the anti
tumor efficacy. Once entered the tumor lesion engineered T cells are assumed to efficiently 
recycle lytic capacity and to kill multiple targets. While this is suggested by in vitro 
evidences formal in vivo confirmation is still lacking.  
A beneficial effector celltotarget cell ratio at the tumor site is likely to be required for 
efficient target cell lysis.  Higher numbers of engineered T cells applied per dose are likely to 
increase clinical efficacy, an estimation based on clinical data, however, is not yet available. 
Current trials are applying up to 1010 cells per dose. These and higher numbers of 
engineered T cells can be generated by current expansion protocols; cells with the optimal 
phenotype for adoptive transfer, however, may not be generated under these conditions. 
Short term amplification protocols are therefore discussed for both TILs from melanoma 
lesions and for engineered T cells. 
Autoimmunity may result from offtarget T cell activation against healthy tissues which 
physiologically express low levels of the targeted antigen. A number of socalled “tumor
associated antigens” are also expressed on healthy tissues, although frequently at lower 
levels, e.g., MART1 on melanocytes. When targeting those antigens, vitiligo and deafness 
(Offringa 2009; Johnson et al. 2009a) to a certain degree is frequently observed; uveitis and 
inner ear toxicity were observed upon adoptive therapy with TCR engineered T cells 
(Johnson et al. 2009b). Since nearly all tumorassociated antigens are selfantigens, strategies 
need to be adopted to ensure offtarget toxicities are kept to a minimum although toxicity 









target toxicities generally predict for antitumour responses (Overwijk et al. 2003). It is 
currently under investigation whether T cells with lowavidity TCR are less prone to induce 
such unwanted side effects. Toxicity, however, can be controlled using steroids to deplete 
modified T cells locally (Johnson et al. 2009b) or systemically as has been the case in CAR 
targeting carboanhydrase IX (G250), a renal cell carcinoma antigen also expressed at low 
levels on bile duct epithelia (Lamers et al. 2006a; Lamers et al. 2006b).  
One of the major hurdles of redirected immunotherapy of melanoma is the heterogeneity of 
antigen expression within the malignant lesions which negatively affects the longterm 
therapeutic efficacy of the approach. Whereas melanotransferinpositive or HMWMAA
positive melanoma cells may be successfully eliminated by redirected T cells engineered 
with the respective CAR, antigennegative tumor cells, however, will not be recognized by 
those T cells. The limitation may be overcome by utilizing mixed T cell populations 
modified with different CARs recognizing different antigens of the same tumor. On the 
other hand, activation of proinflammatory immune cells in the tumor microenvironment 
led to the speculation whether IL2, secreted in high concentrations by activated T cells, may 
attract a second wave of nonantigen restricted effector cells which eradicate antigen
negative tumor cells. Experiments with antibodycytokine fusion proteins indicate that at 
least in an animal model antigennegative melanoma cells are indeed eliminated when co
inoculated with antigenpositive melanoma cells and that the T cell mediated immune 
response is followed by a longlived transferable protective immunity (Becker et al. 1996). 
As far as safety concerns, insertional mutagenesis by retro or lentiviral gene transfer of the 
TCR or CAR encoding transgene also needs to be addressed. While more than 100 patients 
have been treated so far, malignant transformation of blood T cells has not been observed in 
any case which is in contrast to genetic modification of hematopoietic stem cells. 
Retrovirally modified, mature polyclonal T cells seem not to produce clonal amplification 
upon adoptive transfer (Newrzela et al. 2008). Apart from that, the search for a safer vector 
system using nonintegrating vectors (Perro et al. 2010), RNA transfer (Zhao et al. 2010), or 
targeted recombination (Carroll 2008) into safe sites is still ongoing. Once adoptively 
transferred, controlling the engineered T cell in vivo represents an important option. Novel 
gene suicide systems using tagged receptor molecules which can be targeted by T cell 
depleting antibodies in vivo (Kieback et al. 2008) and inducible caspasebased suicide 
systems (de Witte et al. 2008) have recently been developed to permit specific depletion of 










Current therapeutic strategies in oncology aim to eliminate all cancer cells within a tumor 
lesion. The histology, however, teaches us that a variety of different cancer cells make up 
most tumor tissues in addition to nonmalignant cells which form the socalled stroma. 
Transplantation of individual cancer cell subsets from melanoma under limiting dilution 
conditions revealed that a subset of cancer cells is capable to induce tumors of the same 
histological phenotype as the parental tumor (AlHajj et al. 2003; Schatton et al. 2008; 
Zabierowski & Herlyn 2008). Transplantation assays moreover revealed that a low number 
of sorted cells, most rigorously one cancer cell, is capable to induce tumors when 
transplanted under appropriate conditions (Quintana et al. 2008). The conclusion drawn 
from these experiments was that melanoma is organized in a hierarchical manner following 







other tumor entities (Ailles & Weissman 2007; Clevers 2011). Low abundance, induction of 
tumors, selfrenewal and differentiation into heterogeneous phenotypes of cancer cells are 
properties postulated for CSCs. While established as early as 1968 (Fiala 1968), the CSC 
paradigm experienced revival when Bonnet and Dick (1997) showed that most subtypes of 
acute myeloid leukemia can be established in their broad diversity by transplantation of a 
defined and rare subset of malignant CD34+ cells fully recapitulating the leukemic 
phenotype (Bonnet & Dick 1997). A variety of cancer stem cells were subsequently identified 
in solid tumors including mammary, prostate, pancreatic and colon carcinoma as well as 
glioma (AlHajj et al. 2003; Dalerba et al. 2007; Singh et al. 2003; RicciVitiani et al. 2007; Li et 
al. 2007). In melanoma, however, the identity of CSCs, their frequency and more even their 
existence in a given lesion is still controversially debated (Marotta & Polyak 2009; Rosen & 
Jordan 2009; Hill 2006; Shackleton et al. 2009; Shackleton & Quintana 2010). A first study 
using the limiting dilution transplantation assay identified a melanoma cell subset which 
exhibits stemlike capacities and expresses CD20 (Fang et al. 2005). Under more strict assay 
conditions other groups isolated tumor initiating cells which express either the transporter 
protein ABCB5 (Schatton et al. 2008) or the nerve growth factor receptor CD271 (Boiko et al. 
2010). A recent study from Weissman and colleagues calculated the frequency of 
tumorigenic cells in melanoma of about 1/2000 cells (Boiko et al. 2010). Investigations by 
Quintana et al. (Quintana et al. 2010; Quintana et al. 2008) questioned the existence of any 
melanoma stem cell. Transplantation under more rigorous conditions revealed that nearly 
every forth randomly chosen melanoma cell (1/2 – 1/15) is capable to induce melanoma in 
the appropriate host and that the potential of melanoma induction is not associated with 
any surface marker tested so far. This demonstrates that the number of potential CSCs in 
melanoma may not be necessarily low and that the melanoma inducing capacity is not 
associated with a fixed phenotype of melanoma cells while these cells reconstitute the exact 
marker pattern of the parental tumor irrespective of marker positivity or negativity. The 
observations imply that reversible transformation of the melanoma cell is crucial for the 
initiation of a new melanoma after xenotransplantation and that a substantial number of 
melanoma cells are capable to undergo this transformation process. The melanoma cell may 
express a variety of different markers at the time of isolation from an established lesion, 
after transplantation, however, the cell reprograms to the tumor initiating phenotype.  
Another so far not appropriately recognized consequence of the CSC paradigm is that a 
hierarchy of cancer cells is preserved in an established tumor lesion. If the hypothesis is 
fulfilled for melanoma, some melanoma cells maintain tumor progression whereas the bulk 
of tumor cells does not. Consequently, specific ablation of the properly rare melanoma 
sustaining cells, which may but must not be identical to CSCs identified by the 
transplantation assay, from the established tumor tissue must inevitably lead to a decay of 
the tumor lesion independently of targeting the cancer cell mass. A most recent study 
addressed whether specific elimination of defined melanoma cells from an established 
lesion causes tumor regression (Schmidt et al. 2011). By adoptive transfer of engineered T 
cells with a CD20 specific CAR established xenotransplanted tumors could be completely 
eradicated whereas targeted elimination of any random melanoma cell population did not. 
The frequency of CD20+ melanoma cells in the tumor tissues was about 1  2% irrespective 
of the melanoma subtype; in about 20% of melanoma samples no CD20+ melanoma cells 
could be detected. In those tumors, consequently, adoptive transfer of CD20 redirected T 
cells did not induce tumor regression. Reexpression of CD20 in those tumor cells, 









that CD20 per se does not induce the capacity. CD20 expression, however, indicates 
melanoma cells in an established lesion with such tumor maintaining properties. The 
observations have substantial impact on the future design of melanoma therapy.  
First, eradication of hierarchically organized melanoma needs to eliminate those cancer cells 
which maintain melanoma progression. Elimination of any other cancer cell populations 
will debulk the tumor lesion and induce rapid tumor regression but the tumor will 
inevitably relapse due to surviving melanoma sustaining cells. The prediction reflects the 
clinical observation of frequent melanoma relapse after chemotherapy and radiation.  
Second, melanoma maintaining cells are rare and unlikely to be eliminated by random 
targeting as provided by most therapeutic agents. Specific targeting by cytotoxic T cells 
redirected towards CD20 or by CD20specific therapeutic antibodies like Rituxan™ 
(rituximab) or Arzerra™ (ofatumumab) will be required. 
Third, melanoma maintaining cells like other CSCs will less replicate than the majority of 
cancer cells making antiproliferative drugs less efficient. Moreover, melanoma CSCs 
express transporter molecules like ABCB5 (Schatton et al. 2008) which efficiently counteract 
chemotherapy. Both properties together contribute to CSC resistance towards a variety of 
physiological and pharmaceutical signals which is frequently described as “dormancy”. The 
dormant state, however, reactivates under so far unknown conditions resulting in 
melanoma relapse.  
Forth, the prevalence of CD20+ melanoma maintaining cells in a tumor lesion may correlate 
with prognosis. It is unresolved, however, whether those cells accumulate during tumor 
progression and metastasis. 
Fifth, functional and phenotypic plasticity of melanoma maintaining cells may require 
continuous presence of therapeutic agents specifically targeting those cells which freshly 
gained melanoma initiating capacities. Clonal evolution of genetic and epigenetic 
modifications may moreover contribute to cancer cell heterogeneity. In their therapeutic 
approach, Schmidt and colleagues (2011) used engineered T cells which are known to 
penetrate tissues, scan for targets and persist for longterm acting as an antigenspecific 
guardian. This is a major advantage of cellular therapy in comparison to other drugs which 
need to be present in therapeutic levels over long times which in the case of melanoma may 
be years. It will therefore be of benefit to debulk the tumor mass by conventional therapy in 






Current trials using melanoma TILs show first promising results, the efficacy in longterm 
needs to be confirmed. Using artificially redirected T cells previous and ongoing phase I 
studies demonstrate the feasibility in generating suitable numbers of genemodified T cells 
for adoptive transfer. Each trial is being performed with CARs and TCRs which have been 
empirically optimised and possess subtle but significant differences suggesting that the 
direct comparison between clinical trial outcomes may not be possible. While 
lymphodepletion prior T cell therapy is widely accepted, substitution of IL2 in high, 
medium or low doses is still a matter of debate. As such, it is likely that some basic 
formulations will need to be determined before the field moves on towards larger, multi
centre clinical testing of modified T cells.  
There are currently clear limitations in adoptive immunotherapy of melanoma and of other 







generated for each patient. Whilst T cells can be produced for early phase trials, the ability 
to generate sufficient cells to perform large scale trials is currently beyond the capabilities of 
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Hutchinson Cancer 
Center, Seattle, USA 
NCT00045149 
TIL MART1 none I 
Marcus Butler, Dana 
Farber Cancer Institute, 
Boston, USA 
NCT00512889 
TIL unknown IL12  I/II 
Steven A. Rosenberg, 
NIH, Bethesda, USA 
NCT01236573 
young TIL unknown none II 
Steven A. Rosenberg, 
NIH, Bethesda, USA 
NCT01118091 
young TIL unknown none II 
Steven A. Rosenberg, 
NIH, Bethesda, USA 
NCT00513604 
T cells MART1 TCR I/II 
Brigitte Dreno, CHU de 
Nantes, Nantes, France 
NCT00720031 
T cells MART1 TCR I 
Steven A. Rosenberg, 
NIH, Bethesda, USA 
(Morgan et al. 
2006) 
T cells MART1 TCR II 
Antoni Ribas, UCLA, 




NYEso1 TCR I/II 
Aude Chapuis, Fred 
Hutchinson Cancer 




VEGFR2 CAR I/II 
Steven A. Rosenberg, 
NIH, Bethesda, USA 
NCT01218867 
Table 1. Clinical trials in the adoptive immunotherapy of melanoma. 
As a system eminent limitation the TIL approach is limited by the lack of knowledge of 
melanoma specificity and the failure to isolate TILs in sufficient numbers from all tumor 
lesions. The CAR approach, on the other hand, is limited to targets on the cell surface while 
intracellular antigens cannot be targeted; the TCR approach is limited to proper MHC 
expression and antigen presentation. While novel strategies are currently explored by 
combining the advantages and eliminating the limitations, the key aspect for adoptive 









tumor tissue. In the tumor tissue infiltrating T cells experience the counterattack by the 
immune suppressive environment provided by suppressive cytokines and regulatory cells. 
Different T cell subsets may be more effective than others in resisting repression, eliminating 
regulatory T cells by lymphodepletion favours therapeutic efficacy of adoptively transferred 
T cells.  
Taken together, strong arguments support the development of cellular immunotherapy of 
melanoma. Since the initial descriptions of the approach, most of the early technological 
hurdles in generating melanomaspecific effector cells have been largely overcome and an 
increasing focus is upon understanding the clinically relevant mechanisms of T cell directed 
therapies and how to make the methodology more economic and widely applicable. 
Adoptive cell therapy in melanoma has moved at a pace and the current clinical and pre
clinical activities will furthermore determine whether adoptive immunotherapy with 
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technologies, which are likely to significantly improve outcomes. Several chapters cover surgical techniques
and other present very rare or challenging clinical cases of melanoma and how these were treated. The book
is geared towards informing clinicians and even patients how melanoma arises, what tools are available and
which decisions need to be made by patients and their families in order to treat this devastating disease.
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